Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.

Publication Type:

Journal Article


Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 26, Issue 4, p.527-34 (2008)


2008, Benchmarking, Brain Neoplasms, Clinical Trials, Phase II as Topic, Disease-Free Survival, Humans, MELANOMA, Meta-Analysis as Topic, Multivariate Analysis, Prognosis, Public Health Sciences Division, Research Design, sample size, Skin Neoplasms, Survival Analysis, Survival Rate


Objective tumor response rates observed in phase II trials for metastatic melanoma have historically not provided a reliable indicator of meaningful survival benefits. To facilitate using overall survival (OS) or progression-free survival (PFS) as an endpoint for future phase II trials, we evaluated historical data from cooperative group phase II trials to attempt to develop benchmarks for OS and PFS as reference points for future phase II trials.